AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT04659447
Drug: Platelet-Rich Plasma
RxNorm normalized name: PLATELET-RICH PLASMA, AUTOLOGOUS
DrugBank: Platelet Rich Plasma (DB19295)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 36 ml of peripheral blood is extracted from patients, and 4 ml of 3.8% sodium citrate is added for anticoagulation. After centrifugation for 2 times, 4 ml platelet-rich plasma will be prepared.Four semitendinosus tendons and gracilis tendons are prepared.
Trial: NCT00457093
Drug: glargine
RxNorm normalized name: Insulin Glargine
DrugBank: Insulin glargine (DB00047)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00457093
Drug: detemir
RxNorm normalized name: Detemir
DrugBank: Insulin detemir (DB01307)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Trial: NCT02095444
Drug: Menstrual blood stem cells
RxNorm normalized name: Longeveron mesenchymal stem cells
DrugBank: Allogenic bone marrow-derived mesenchymal stem cells (DB18032)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10\*7 cells/kg, intravenous injection for 4 times during two weeks
Trial: NCT03109418
Drug: Ketamine
RxNorm normalized name: Ketamine
DrugBank: Ketamine (DB01221)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: OSA patients receiving standard inhaled anesthesia combined with a low-dose ketamine infusion in which dosage will be based on ideal or adjust body weight
Trial: NCT01597934
Drug: Group A (Zeffix, Sebivo, Hepsera)
RxNorm normalized name: meningococcal group A polysaccharide
DrugBank: Neisseria meningitidis group a capsular polysaccharide diphtheria toxoid conjugate antigen (DB10798)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Maintaining LAM/LdT+ADV combination Lamivudine 100mg / Telbivudine 600mg +Adefovir 10mg
Trial: NCT01597934
Drug: Group B (Baraclude, Viread)
RxNorm normalized name: meningococcal group B vaccine
DrugBank: Neisseria meningitidis serogroup B recombinant LP2086 A05 protein variant antigen (DB10284)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Switching to ETV plus TDF combination Entecavir 1.0mg + Tenofovir 300mg
Trial: NCT01054339
Drug: rAAV1-CB-hAAT
RxNorm normalized name: rAAV1-CB-hAAT
DrugBank: rAAV1-CB-hAAT (DB18724)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Recombinant adeno-associated virus vector expressing human alpha-1 antitrypsin
Trial: NCT00722410
Drug: Polyethylene glycol
RxNorm normalized name: Polyethylene Glycol
DrugBank: Polyethylene glycol (DB09287)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral ingestion of 3 liters of polyethylene glycol solution.
Trial: NCT00461851
Drug: Gemcitabine
RxNorm normalized name: Gemcitabine
DrugBank: Gemcitabine (DB00441)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Gemcitabine will be given at a standard dose schedule of 1000 mg/m² on day 1 and 8.
Trial: NCT00461851
Drug: Carboplatin
RxNorm normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Carboplatin will be given on day 1 to an AUC of 5.
Trial: NCT00461851
Drug: Sorafenib
RxNorm normalized name: Sorafenib
DrugBank: Sorafenib (DB00398)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sorafenib will be administered orally daily on days 2-19 at 400 mg bid
Trial: NCT00699361
Drug: Pantoprazole
RxNorm normalized name: Pantoprazole
DrugBank: Pantoprazole (DB00213)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pantoprazole 160 mg I.V.
Trial: NCT00699361
Drug: Pantoprazole
RxNorm normalized name: Pantoprazole
DrugBank: Pantoprazole (DB00213)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pantoprazole 160 mg intravenously (IV)
Trial: NCT02340936
Drug: LR-ESHAP (lenalidomide 5 mg)
RxNorm normalized name: lenalidomide 5 MG
DrugBank: Lenalidomide (DB00480)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 3 cycles of lenalidomide 5mg, etoposide, methylprednisolone, cisplatin, cytarabine and rituximab every 3 weeks.
Trial: NCT02340936
Drug: LR-ESHAP (lenalidomide 10 mg)
RxNorm normalized name: lenalidomide 10 MG
DrugBank: Lenalidomide (DB00480)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 3 cycles of lenalidomide 10mg, etoposide, methylprednisolone, cisplatin, cytarabine and rituximab every 3 weeks.
Trial: NCT02340936
Drug: LR-ESHAP (lenalidomide 15 mg)
RxNorm normalized name: lenalidomide 15 MG
DrugBank: Lenalidomide (DB00480)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 3 cycles of lenalidomide 15mg, etoposide, methylprednisolone, cisplatin, cytarabine and rituximab every 3 weeks.
Trial: NCT02340936
Drug: LR-ESHAP (lenalidomide 20 mg)
RxNorm normalized name: lenalidomide 20 MG
DrugBank: Lenalidomide (DB00480)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 3 cycles of lenalidomide 20mg, etoposide, methylprednisolone, cisplatin, cytarabine and rituximab every 3 weeks.
Trial: NCT02798172
Drug: Alogliptin and Metformin
RxNorm normalized name: Alogliptin and metformin only product
DrugBank: Metformin (DB00331)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: The patients in the control group were given metformin (1,000 mg, bid po) and the patients in the intervention group were given metformin (500 mg, bid po) combined with alogliptin (25 mg, qd po)
Trial: NCT03260881
Drug: Liraglutide Pen Injector [Victoza]
RxNorm normalized name: liraglutide Pen Injector [Victoza]
DrugBank: Liraglutide (DB06655)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Study subjects will be randomized in two groups of 20 patients to receive additional liraglutide, (L-group) or to remain on current treatment or placebo (D-group).
Trial: NCT03260881
Drug: matching liraglutide-placebo pre-filled pens
DrugBank: Liraglutide (DB06655)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Study subjects will be randomized in two groups of 20 patients to receive additional liraglutide, (L-group) or to remain on current treatment or placebo (D-group).
Trial: NCT04360889
Drug: Tocopherol
RxNorm normalized name: tocopherol
DrugBank: Tocopherol (DB11251)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: patients with lower limb lymphedema receiving conservative therapy (elastic compression, to which are added preparations with antioxidant endotheliotropic activity (Tocopherol-400 IU/day)
Trial: NCT01572844
Drug: Sodium thiosulfate
RxNorm normalized name: Sodium Thiosulfate
DrugBank: Thiosulfuric acid (DB09499)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Following treatment with FCO2 laser, 4 ml of 5% Sodium Thiosulfate solution will be applied to the treatment site only. Subjects will receive a total of 8-10 treatments over a 6 month period.
Trial: NCT03776864
Drug: Umbralisib
RxNorm normalized name: Umbralisib
DrugBank: Umbralisib (DB14989)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given PO
Trial: NCT00983944
Drug: etoposide
RxNorm normalized name: Etoposide
DrugBank: Etoposide (DB00773)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV or orally
Trial: NCT00983944
Drug: prednisone
RxNorm normalized name: Prednisone
DrugBank: Prednisone (DB00635)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given IV or orally
Trial: NCT00983944
Drug: vincristine sulfate
RxNorm normalized name: Vincristine Sulfate
DrugBank: Vincristine (DB00541)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given IV or orally
Trial: NCT03243851
Drug: Temozolomide+Metformin
RxNorm normalized name: Temozolomide
DrugBank: Metformin (DB00331)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Low dose temozolomide+metformin for 24 weeks
Trial: NCT03243851
Drug: Temozolomide+Placebo
RxNorm normalized name: Temozolomide
DrugBank: Temozolomide (DB00853)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low dose temozolomide+placebo for 24 weeks
Trial: NCT02571712
Drug: bimatoprost 0.03% plus timolol 0.5%
DrugBank: Timolol (DB00373)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 1 drop of bimatoprost 0.03% plus timolol 0.5% (GANFORT®) instilled in the affected eye once daily.
Trial: NCT01448317
Drug: Alirocumab (Solution)
DrugBank: Alirocumab (DB09302)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Pharmaceutical form: solution~Route of administration: subcutaneous
Trial: NCT02056743
Drug: Fexofenadine 30mg
DrugBank: Fexofenadine (DB00950)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Each group administered Fexofenadine 30mg under fasting conditions.
Trial: NCT02913703
Drug: Ghrelin
RxNorm normalized name: Ghrelin
DrugBank: Lenomorelin (DB11895)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Boluses of Ghrelin will be given over a 1 minute period at 3 ug/kg. Ensure (2 cans) will also be given.
Trial: NCT03388346
Drug: Ga-68 PSMA-HBED-CC PET
RxNorm normalized name: Psma-hbed-CC Ga-68
DrugBank: Gallium Ga-68 gozetotide (DB16019)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ga-68 PSMA-HBED-CC is an investigational PET drug (radionuclide), that binds to the prostate specific receptors. The dose will be about 5mCi (range 3-7 mCi) and administered intravenously.
Trial: NCT00330577
Drug: timolol maleate 0.5%
RxNorm normalized name: TIMOLOL MALEATE 0.5% GEL,OPH
DrugBank: Timolol (DB00373)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00497939
Drug: Saw palmetto and sanmiaoshan capsule
RxNorm normalized name: Saw palmetto
DrugBank: Saw palmetto (DB14360)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00898950
Drug: Aspirin
RxNorm normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Aspirin 75mgs/day orally for 2 weeks.
Trial: NCT00898950
Drug: Aspirin
RxNorm normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 300mgs/day orally for 2 weeks
Trial: NCT00898950
Drug: Aspirin
RxNorm normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: aspirin 900mgs QID orally for 2 weeks
Trial: NCT00330577
Drug: latanoprost/timolol fixed combination
DrugBank: Timolol (DB00373)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00940524
Drug: Dasatinib, Mitoxantrone, Cytarabine
DrugBank: Cytarabine (DB00987)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: INDUCTION- Dasatinib† (dose levels 1-3) \*continuously Cytarabine 3 g/m2 IV over 3 hours Mitoxantrone 80 mg/m2 IV Myeloid growth factor on day 7 until ANC \> 1,000/μl x 2 days Allopurinol 300 mg BID-TID x 7 days (starting 6-12 hours prior to chemotherapy) Dexamethasone 0.1% eye drops q6h while on cytarabine (start prior to the first dose of cytarabine and continuing at least 24 hours after the last dose) IT Methotrexate 12 mg days 2 and 4~CONSOLIDATION A-Dasatinib† (dose levels 1-3) \*continuously Vincristine 2 mg IV Dexamethasone 10 mg/m2/d days 2 to 29, then taper over 10 days Sulfamethoxazole/Trimethoprim 1 DS BID three times weekly days 2 to 29, then BID daily days 30 to 45 IT Methotrexate 12 mg days 8, 15, 22 and 29
Trial: NCT00075634
Drug: decitabine
RxNorm normalized name: Decitabine
DrugBank: Decitabine (DB01262)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given IV
Trial: NCT01813630
Drug: DA-3002
RxNorm normalized name: DAS-181
DrugBank: DAS-181 (DB15313)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01462422
Drug: Misoprostol
RxNorm normalized name: Misoprostol
DrugBank: Misoprostol (DB00929)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Selective administration of 800 mcg sublingual misoprostol to women with at least 350 mL blood loss within 1 hour following delivery
Trial: NCT01462422
Drug: Misoprostol
RxNorm normalized name: Misoprostol
DrugBank: Misoprostol (DB00929)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Universal administration of 600 mcg oral misoprostol given to all women within 5 minutes of delivery of the baby
Trial: NCT03479203
Drug: Electronic Cigarette Aerosol
RxNorm normalized name: tetracaine
DrugBank: Tetracaine (DB09085)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 16 two-second-long puffs from a non-nicotinized electronic cigarette.
Trial: NCT04509635
Drug: Cetuximab
RxNorm normalized name: Cetuximab
DrugBank: Cetuximab (DB00002)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Cetuximab is used for only patients with ctDNA test RAS wild type.
Trial: NCT03922919
Drug: Cefotaxime Injection
RxNorm normalized name: cefotaxime Injection
DrugBank: Cefotaxime (DB00493)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Systematic use of cefotaxime.
Trial: NCT03922919
Drug: Cefotaxime/ceftriaxone
DrugBank: Cefotaxime (DB00493)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: ceftriaxone or cefotaxime infusion at the discretion of the prescribing physician
Trial: NCT02362256
Drug: Naltrexone
RxNorm normalized name: Naltrexone
DrugBank: Naltrexone (DB00704)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02362256
Drug: Clonidine
RxNorm normalized name: Clonidine
DrugBank: Clonidine (DB00575)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02362256
Drug: Lorazepam
RxNorm normalized name: Lorazepam
DrugBank: Lorazepam (DB00186)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02134912
Drug: crizotinib
RxNorm normalized name: Crizotinib
DrugBank: Crizotinib (DB08865)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Given PO
Trial: NCT04177706
Drug: Ketamine Hydrochloride
RxNorm normalized name: Ketamine Hydrochloride
DrugBank: Ketamine (DB01221)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Participants receiving the active study medication will receive 60 mg ketamine twice per week for four weeks under clinical supervision.
Trial: NCT01228669
Drug: NNC 0172-0000-2021
RxNorm normalized name: NNC-55-0396 free base
DrugBank: NNC-55-0396 free base (DB17037)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose injected i.v. (into a vein). Each treatment dose is assessed for safety before escalating to next dose
Trial: NCT01228669
Drug: NNC 0172-0000-2021
RxNorm normalized name: NNC-55-0396 free base
DrugBank: NNC-55-0396 free base (DB17037)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose injected s.c. (under the skin). Each treatment dose is assessed for safety before escalating to next dose.
Trial: NCT02646358
Drug: Vepoloxamer
RxNorm normalized name: Vepoloxamer
DrugBank: Poloxamer 188 (DB11333)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03065569
Drug: Bupivacaine
RxNorm normalized name: Bupivacaine
DrugBank: Bupivacaine (DB00297)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 16 mL of 0.125% bupivacaine
Trial: NCT02134912
Drug: pemetrexed disodium
RxNorm normalized name: Pemetrexed Disodium
DrugBank: Pemetrexed (DB00642)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Given IV
Trial: NCT04715958
Drug: Perflutren Lipid Microspheres
RxNorm normalized name: perflutren lipid microspheres
DrugBank: Perflutren (DB00556)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given IV
Trial: NCT00184366
Drug: efalizumab
RxNorm normalized name: Efalizumab
DrugBank: Efalizumab (DB00095)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: efalizumab
Trial: NCT03710460
Drug: Dapagliflozin
RxNorm normalized name: Dapagliflozin
DrugBank: Dapagliflozin (DB06292)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 10 mg, one per day before breakfast during 12 weeks.
Trial: NCT03710460
Drug: Dapagliflozin plus Metformin XR
RxNorm normalized name: dapagliflozin / metformin Extended Release Oral Tablet
DrugBank: Metformin (DB00331)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 10/1000 mg, one per day before breakfast during 12 weeks.
Trial: NCT03710460
Drug: Metformin XR
RxNorm normalized name: metformin Extended Release Suspension
DrugBank: Metformin (DB00331)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 1000 mg, one per day before breakfast during 12 weeks.
Trial: NCT00443794
Drug: Ramipril with Thiazide
RxNorm normalized name: Ramipril
DrugBank: Ramipril (DB00178)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Capsule (blinded) oral administration 12 weeks
Trial: NCT00443794
Drug: Thiazide plus atenolol
RxNorm normalized name: Atenolol
DrugBank: Atenolol (DB00335)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Caspule (blinded) for oral administration once daily for 12 weeks
Trial: NCT00443794
Drug: Ramipril plus atenolol
RxNorm normalized name: Ramipril
DrugBank: Ramipril (DB00178)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Capsule ( blinded) for oral administration once daily for 12 weeks
Trial: NCT00443794
Drug: Ramipril plus atenolol plus thiazide
DrugBank: Ramipril (DB00178)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Capsule (blinded) for oral administration once daily for 12 weeeks
Trial: NCT00443794
Drug: POLYCAP
RxNorm normalized name: Atriplex polycarpa pollen
DrugBank: Poly(lactic acid) (DB15037)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Capsule for Oral Administration once daily for 12 weeks
Trial: NCT00443794
Drug: Thiazide + Ramipril+Atenolol+Aspirin
RxNorm normalized name: Ramipril
DrugBank: Ramipril (DB00178)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Capsule (Blinded) for oral administration once daily for 12 weeks
Trial: NCT00443794
Drug: aspirin
RxNorm normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: capsule (Blinded) for oral administration once daily for 12 weeks
Trial: NCT00772980
Drug: Neramexane mesylate
RxNorm normalized name: mesylate
DrugBank: Neramexane (DB04926)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Double-blind treatment period of 17 weeks up to 75 mg Neramexane mesylate per day, 12 weeks follow-up.
Trial: NCT00103935
Drug: Exenatide LAR
RxNorm normalized name: Exenatide
DrugBank: Exenatide (DB01276)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Subcutaneously injected exenatide 5 mcg (0.02 mL) twice daily as lead-in followed by once weekly injected exenatide LAR 0.8 mcg.
Trial: NCT00103935
Drug: Exenatide LAR
RxNorm normalized name: Exenatide
DrugBank: Exenatide (DB01276)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Subcutaneously injected exenatide 5 mcg (0.02 mL) twice daily as lead-in followed by once weekly injected exenatide LAR 2.0 mcg.
Trial: NCT00025090
Drug: cisplatin
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00025090
Drug: mitomycin C
RxNorm normalized name: Mitomycin C
DrugBank: Mitomycin (DB00305)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00979004
Drug: ICA-105665
RxNorm normalized name: ICA-105665
DrugBank: ICA-105665 (DB06089)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral tablet. Dose forms of 50 and 100 mg or placebo will be used. A single dose will be administered that can range from placebo or 100 to 600 mg.
Trial: NCT00370825
Drug: Combination therapy with AmBisome and miltefosine
DrugBank: Miltefosine (DB09031)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00303329
Drug: Deferasirox
RxNorm normalized name: Deferasirox
DrugBank: Deferasirox (DB01609)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Deferasirox available as 125 mg, 250 mg or 500 mg tablets
Trial: NCT00025610
Drug: carboplatin
RxNorm normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00025610
Drug: etoposide
RxNorm normalized name: Etoposide
DrugBank: Etoposide (DB00773)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00025610
Drug: vincristine sulfate
RxNorm normalized name: Vincristine Sulfate
DrugBank: Vincristine (DB00541)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00574834
Drug: Ramipril
RxNorm normalized name: Ramipril
DrugBank: Ramipril (DB00178)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ramipril 20 mg once daily for 6 months
Trial: NCT00574834
Drug: Ramipril+HCTZ
RxNorm normalized name: hydrochlorothiazide / ramipril
DrugBank: Ramipril (DB00178)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ramipril 20 mg and HCTZ 25 mg, both once daily for 6 months
Trial: NCT00713609
Drug: Benzoyl peroxide gel
RxNorm normalized name: Benzoyl Peroxide Gel
DrugBank: Benzoyl peroxide (DB09096)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 5% benzoyl peroxide in a gel applied topically once a day
Trial: NCT00713609
Drug: Tazarotene cream
RxNorm normalized name: Tazarotene Cream
DrugBank: Tazarotene (DB00799)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 0.1 % tazarotene in a cream applied topically once a day
Trial: NCT00060528
Drug: Recombinant Fowlpox-PSA (L155)-TRICOM (PROSTVAC-F/TRICOM)
RxNorm normalized name: RECOMBINANT STABILIZED RSV A PREFUSION F ANTIGEN
DrugBank: Recombinant stabilized RSV A prefusion F antigen (DB18713)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00060528
Drug: Recombinant Vaccinia-PSA (L155)-TRICOM (PROSTVAC-V/TRICOM)
RxNorm normalized name: vaccinia virus
DrugBank: Human vaccinia virus immune globulin (DB14112)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00794235
Drug: Sorafenib (Nexavar), Dacarbazine (DTIC)
DrugBank: Sorafenib (DB00398)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sorafenib: 2x400 mg daily PO (2 tablets (200 mg each) each AM and PM). DAY 1-56.~DTIC: 1-hour IV infusion 1000mg/m2 DAY 14 and 42.
Trial: NCT04354870
Drug: Hydroxychloroquine (HCQ)
DrugBank: Hydroxychloroquine (DB01611)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Loading dose: 600 mg, oral, 1 day Maintenance dose: 200 mg, oral, daily, for 90 days
Trial: NCT01697059
Drug: Piperacillin + Amoxicillin
RxNorm normalized name: Piperacillin
DrugBank: Piperacillin (DB00319)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01964534
Drug: ABI-007
RxNorm normalized name: ABI-007 COMPONENT PACLITAXEL
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: ABI-007 : 125 mg/m² IV /30min (day 1, day 8, day 15)
Trial: NCT01964534
Drug: Gemcitabine
RxNorm normalized name: Gemcitabine
DrugBank: Gemcitabine (DB00441)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 1000 mg/m² IV /30min (day 1, day 8, day 15)
Trial: NCT00050440
Drug: Trabectedin
RxNorm normalized name: Trabectedin
DrugBank: Trabectedin (DB05109)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Trabectedin 1.3 mg/m2 administered intravenously every 21 days.
Trial: NCT00050440
Drug: Dexamethasone
RxNorm normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Dexamethasone 4 mg administered orally (by mouth) the day before the trabectedin dose, 30 minutes before the trabectedin dose, and for 2 days following the trabectedin dose
Trial: NCT03040479
Drug: lasmiditan 200 mg
RxNorm normalized name: lasmiditan 200 MG
DrugBank: Lasmiditan (DB11732)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: single dose
Trial: NCT02005549
Drug: bevacizumab [Avastin]
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 15 mg/kg iv on Day 1 of each 3-week cycle, 5 cycles
Trial: NCT02005549
Drug: docetaxel
RxNorm normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 75 mg/m2 on Day 1 of each 3-week cycle, 6 cycles